NEW YORK (GenomeWeb) – A mathematical model of the benefits of co-testing for cervical cancer screening has shown that the approach could be more cost effective than Pap or human papillomavirus molecular testing alone, in part by reducing unneeded medical procedures. 

The analysis, which was performed by researchers at the University of Southern California Keck School of Medicine and Truven Health Analytics in Cambridge, Massachusetts, was presented last week at the International Society For Pharmacoeconomics and Outcomes Research meeting.